EA201071282A1 - 3-гидроксигепирон для лечения синдрома дефицита внимания и половой дисфункции - Google Patents

3-гидроксигепирон для лечения синдрома дефицита внимания и половой дисфункции

Info

Publication number
EA201071282A1
EA201071282A1 EA201071282A EA201071282A EA201071282A1 EA 201071282 A1 EA201071282 A1 EA 201071282A1 EA 201071282 A EA201071282 A EA 201071282A EA 201071282 A EA201071282 A EA 201071282A EA 201071282 A1 EA201071282 A1 EA 201071282A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sexual dysfunction
hydroxygepiron
attention
treatment
syndrome
Prior art date
Application number
EA201071282A
Other languages
English (en)
Inventor
Стефен Дж. Крамер
Луис Ф. Фейбр
Original Assignee
Фэйбр-Крэймер Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фэйбр-Крэймер Фармасьютикалз, Инк. filed Critical Фэйбр-Крэймер Фармасьютикалз, Инк.
Publication of EA201071282A1 publication Critical patent/EA201071282A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к способу ослабления, предотвращения и лечения синдрома дефицита внимания, половой дисфункции и близких состояний введением некоторых биологически активных метаболитов известного соединения антидепрессанта гепирона. В предпочтительном варианте осуществления соединение представляет 4,4-диметил-3-гидрокси-1-[4-[4-(2-пиримидил)-1-пиперазинил]бутил]-2,6-пиперидиндион (3-ОН-гепирон).
EA201071282A 2008-05-08 2009-05-07 3-гидроксигепирон для лечения синдрома дефицита внимания и половой дисфункции EA201071282A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5155508P 2008-05-08 2008-05-08
PCT/US2009/043146 WO2009137679A1 (en) 2008-05-08 2009-05-07 3-hydroxy gepirone for the treatment of attention deficit disorder and sexual dysfunction

Publications (1)

Publication Number Publication Date
EA201071282A1 true EA201071282A1 (ru) 2011-04-29

Family

ID=41265006

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071282A EA201071282A1 (ru) 2008-05-08 2009-05-07 3-гидроксигепирон для лечения синдрома дефицита внимания и половой дисфункции

Country Status (12)

Country Link
US (1) US20090281111A1 (ru)
EP (1) EP2273991A4 (ru)
JP (1) JP2011519953A (ru)
KR (1) KR20110013385A (ru)
CN (1) CN102026639A (ru)
AU (1) AU2009244197A1 (ru)
BR (1) BRPI0912516A2 (ru)
CA (1) CA2720133A1 (ru)
EA (1) EA201071282A1 (ru)
IL (1) IL209187A0 (ru)
MX (1) MX2010012146A (ru)
WO (1) WO2009137679A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281112A1 (en) * 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20030220346A1 (en) * 2000-12-18 2003-11-27 Kramer Stephen J. Use of bioactive metabolites of gepirone for the treatment of psychological disorders
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US7153858B2 (en) * 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds

Also Published As

Publication number Publication date
KR20110013385A (ko) 2011-02-09
MX2010012146A (es) 2010-12-01
CN102026639A (zh) 2011-04-20
BRPI0912516A2 (pt) 2015-10-13
EP2273991A4 (en) 2012-05-02
WO2009137679A1 (en) 2009-11-12
EP2273991A1 (en) 2011-01-19
JP2011519953A (ja) 2011-07-14
US20090281111A1 (en) 2009-11-12
AU2009244197A1 (en) 2009-11-12
CA2720133A1 (en) 2009-11-12
IL209187A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
EA200870462A1 (ru) Производные бифениламидлактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
NZ597379A (en) Therapeutic compounds and compositions
EA200870461A1 (ru) Производные лактама циклогексилимидазола в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1
EA201000007A1 (ru) Производные индазоламида
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA201391236A1 (ru) Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
DK2049513T3 (da) Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201001358A1 (ru) Активаторы глюкокиназы
EA201290516A1 (ru) Гетероароматические производные соединения фенилимидазола в качестве ингибиторов фермента pde10a
ATE497809T1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
GT200600105A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.
PE20100083A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
EA201071282A1 (ru) 3-гидроксигепирон для лечения синдрома дефицита внимания и половой дисфункции
EA201001367A1 (ru) Производные карбоксамид-гетероарила для лечения диабета
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
ATE533488T1 (de) Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen
EA200970871A1 (ru) Новое терапевтическое применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania